Skip to main content
Top
Published in: Advances in Therapy 3/2018

Open Access 01-03-2018 | Review

A Review of the Role of the Pharmacist in Heart Failure Transition of Care

Authors: Sarah L. Anderson, Joel C. Marrs

Published in: Advances in Therapy | Issue 3/2018

Login to get access

Abstract

This article reviews current literature on the role of pharmacists in the transition of care (TOC) for patients with heart failure (HF) and the impact of their contributions on therapeutic and economic outcomes. Optimizing the TOC for patients with HF from the hospital to the community/home is crucial for improving outcomes and decreasing high rates of hospital readmissions, which are associated with increased morbidity, mortality, and costs. A multidisciplinary team approach to the management of patients with HF facilitates the transition from the hospital to the ambulatory care setting, allowing for the consideration of medical, pharmacological, and lifestyle variables that impact the care of individual patients. Pharmacist participation on both inpatient and outpatient teams can provide a variety of services that have been shown to reduce hospital readmission rates and benefit patient management and treatment. These include medication reconciliation, patient education, medication dosage titration and adjustment, patient monitoring, development of disease management pathways, promotion of medication adherence, and postdischarge follow-up. In addition, as new pharmacologic treatments for HF become available, pharmacists can raise awareness of optimal drug use by maximizing education related to efficacy (e.g., adherence) and safety (e.g., potential side effects and drug interactions). Improving understanding of HF and its treatment will enable increased pharmacist involvement in the TOC that should lead to improved outcomes and reduced healthcare costs.
Funding: Novartis.
Literature
1.
go back to reference Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.CrossRefPubMedPubMedCentral Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.CrossRefPubMedPubMedCentral
3.
go back to reference Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–319.CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–319.CrossRefPubMed
4.
go back to reference Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.CrossRefPubMed Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.CrossRefPubMed
5.
go back to reference Milfred-Laforest SK, Chow SL, Didomenico RJ, et al. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. J Card Fail. 2013;19:354–69.CrossRefPubMed Milfred-Laforest SK, Chow SL, Didomenico RJ, et al. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. J Card Fail. 2013;19:354–69.CrossRefPubMed
8.
go back to reference Kitts NK, Reeve AR, Tsu L. Care transitions in elderly heart failure patients: current practices and the pharmacist’s role. Consult Pharm. 2014;29:179–90.CrossRefPubMed Kitts NK, Reeve AR, Tsu L. Care transitions in elderly heart failure patients: current practices and the pharmacist’s role. Consult Pharm. 2014;29:179–90.CrossRefPubMed
9.
go back to reference Murray MD. Implementing pharmacy practice research programs for the management of heart failure. Pharm World Sci. 2010;32:546–8.CrossRefPubMed Murray MD. Implementing pharmacy practice research programs for the management of heart failure. Pharm World Sci. 2010;32:546–8.CrossRefPubMed
10.
go back to reference Salas CM, Miyares MA. Implementing a pharmacy resident run transition of care service for heart failure patients: effect on readmission rates. Am J Health Syst Pharm. 2015;72(11 Suppl 1):S43–7.CrossRefPubMed Salas CM, Miyares MA. Implementing a pharmacy resident run transition of care service for heart failure patients: effect on readmission rates. Am J Health Syst Pharm. 2015;72(11 Suppl 1):S43–7.CrossRefPubMed
11.
go back to reference Rodgers JE, Stough WG. Underutilization of evidence-based therapies in heart failure: the pharmacist’s role. Pharmacotherapy. 2007;27:18S–28S.CrossRefPubMed Rodgers JE, Stough WG. Underutilization of evidence-based therapies in heart failure: the pharmacist’s role. Pharmacotherapy. 2007;27:18S–28S.CrossRefPubMed
12.
go back to reference Kalisch LM, Roughead EE, Gilbert AL. Improving heart failure outcomes with pharmacist-physician collaboration: how close are we? Future Cardiol. 2010;6:255–68.CrossRefPubMed Kalisch LM, Roughead EE, Gilbert AL. Improving heart failure outcomes with pharmacist-physician collaboration: how close are we? Future Cardiol. 2010;6:255–68.CrossRefPubMed
13.
go back to reference Cohen MJ, Shaykevich S, Cawthon C, Kripalani S, Paasche-Orlow MK, Schnipper JL. Predictors of medication adherence postdischarge: the impact of patient age, insurance status, and prior adherence. J Hosp Med. 2012;7:470–5.CrossRefPubMedPubMedCentral Cohen MJ, Shaykevich S, Cawthon C, Kripalani S, Paasche-Orlow MK, Schnipper JL. Predictors of medication adherence postdischarge: the impact of patient age, insurance status, and prior adherence. J Hosp Med. 2012;7:470–5.CrossRefPubMedPubMedCentral
14.
go back to reference Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.CrossRefPubMed Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.CrossRefPubMed
15.
go back to reference Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168:721–30.CrossRefPubMed Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168:721–30.CrossRefPubMed
16.
go back to reference Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64:2281–93.CrossRefPubMedPubMedCentral Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64:2281–93.CrossRefPubMedPubMedCentral
17.
go back to reference Cooper LB, Hernandez AF. Assessing the quality and comparative effectiveness of team-based care for heart failure: who, what, where, when, and how. Heart Fail Clin. 2015;11:499–506.CrossRefPubMedPubMedCentral Cooper LB, Hernandez AF. Assessing the quality and comparative effectiveness of team-based care for heart failure: who, what, where, when, and how. Heart Fail Clin. 2015;11:499–506.CrossRefPubMedPubMedCentral
18.
go back to reference Cheng JW, Cooke-Ariel H. Pharmacists’ role in the care of patients with heart failure: review and future evolution. J Manag Care Pharm. 2014;20:206–13.PubMed Cheng JW, Cooke-Ariel H. Pharmacists’ role in the care of patients with heart failure: review and future evolution. J Manag Care Pharm. 2014;20:206–13.PubMed
19.
go back to reference Gattis WA, Hasselblad V, Whellan DJ, O’Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159:1939–45.CrossRefPubMed Gattis WA, Hasselblad V, Whellan DJ, O’Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159:1939–45.CrossRefPubMed
20.
go back to reference Martinez AS, Saef J, Paszczuk A, Bhatt-Chugani H. Implementation of a pharmacist-managed heart failure medication titration clinic. Am J Health Syst Pharm. 2013;70:1070–6.CrossRefPubMed Martinez AS, Saef J, Paszczuk A, Bhatt-Chugani H. Implementation of a pharmacist-managed heart failure medication titration clinic. Am J Health Syst Pharm. 2013;70:1070–6.CrossRefPubMed
21.
go back to reference Luder HR, Frede SM, Kirby JA, et al. TransitionRx: impact of community pharmacy postdischarge medication therapy management on hospital readmission rate. J Am Pharm Assoc. 2003;2015(55):246–54. Luder HR, Frede SM, Kirby JA, et al. TransitionRx: impact of community pharmacy postdischarge medication therapy management on hospital readmission rate. J Am Pharm Assoc. 2003;2015(55):246–54.
22.
go back to reference Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med. 2007;146:714–25.CrossRefPubMed Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med. 2007;146:714–25.CrossRefPubMed
23.
go back to reference Warden BA, Freels JP, Furuno JP, Mackay J. Pharmacy-managed program for providing education and discharge instructions for patients with heart failure. Am J Health Syst Pharm. 2014;71:134–9.CrossRefPubMed Warden BA, Freels JP, Furuno JP, Mackay J. Pharmacy-managed program for providing education and discharge instructions for patients with heart failure. Am J Health Syst Pharm. 2014;71:134–9.CrossRefPubMed
25.
go back to reference Gunadi S, Upfield S, Pham ND, Yea J, Schmiedeberg MB, Stahmer GD. Development of a collaborative transitions-of-care program for heart failure patients. Am J Health Syst Pharm. 2015;72:1147–52.CrossRefPubMed Gunadi S, Upfield S, Pham ND, Yea J, Schmiedeberg MB, Stahmer GD. Development of a collaborative transitions-of-care program for heart failure patients. Am J Health Syst Pharm. 2015;72:1147–52.CrossRefPubMed
26.
go back to reference Fera T, Anderson C, Kanel KT, Ramusivich DL. Role of a care transition pharmacist in a primary care resource center. Am J Health Syst Pharm. 2014;71:1585–90.CrossRefPubMed Fera T, Anderson C, Kanel KT, Ramusivich DL. Role of a care transition pharmacist in a primary care resource center. Am J Health Syst Pharm. 2014;71:1585–90.CrossRefPubMed
28.
go back to reference Odum L, Whaley-Connell A. The role of team-based care involving pharmacists to improve cardiovascular and renal outcomes. Cardiorenal Med. 2012;2:243–50.CrossRefPubMedPubMedCentral Odum L, Whaley-Connell A. The role of team-based care involving pharmacists to improve cardiovascular and renal outcomes. Cardiorenal Med. 2012;2:243–50.CrossRefPubMedPubMedCentral
29.
go back to reference Thompson CA. Integrated pharmacy practice helps reduce heart failure readmission rate. Am J Health Syst Pharm. 2012;69:1540–1.CrossRefPubMed Thompson CA. Integrated pharmacy practice helps reduce heart failure readmission rate. Am J Health Syst Pharm. 2012;69:1540–1.CrossRefPubMed
30.
go back to reference Coons JC, Fera T. Multidisciplinary team for enhancing care for patients with acute myocardial infarction or heart failure. Am J Health Syst Pharm. 2007;64:1274–8.CrossRefPubMed Coons JC, Fera T. Multidisciplinary team for enhancing care for patients with acute myocardial infarction or heart failure. Am J Health Syst Pharm. 2007;64:1274–8.CrossRefPubMed
31.
32.
go back to reference Murray MD, Ritchey ME, Wu J, Tu W. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. Arch Intern Med. 2009;169:757–63.CrossRefPubMed Murray MD, Ritchey ME, Wu J, Tu W. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. Arch Intern Med. 2009;169:757–63.CrossRefPubMed
33.
go back to reference Eggink RN, Lenderink AW, Widdershoven JW, van den Bemt PM. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci. 2010;32:759–66.CrossRefPubMedPubMedCentral Eggink RN, Lenderink AW, Widdershoven JW, van den Bemt PM. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci. 2010;32:759–66.CrossRefPubMedPubMedCentral
34.
go back to reference Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med. 2004;164:709–20.CrossRefPubMed Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med. 2004;164:709–20.CrossRefPubMed
35.
go back to reference Page RL 2nd, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–69.CrossRefPubMed Page RL 2nd, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–69.CrossRefPubMed
36.
go back to reference Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim–sulfamethoxazole with and without concomitant medications. Ann Pharmacother. 2013;47:1618–26.CrossRefPubMed Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim–sulfamethoxazole with and without concomitant medications. Ann Pharmacother. 2013;47:1618–26.CrossRefPubMed
37.
go back to reference Dal Negro R, Turco P, Pomari C, Monici-Preti P. Effect of various disease states on theophylline plasma levels and on pulmonary function in patients with chronic airway obstruction treated with a sustained release theophylline preparation. Int J Clin Pharmacol Ther Toxicol. 1987;25:401–5. Dal Negro R, Turco P, Pomari C, Monici-Preti P. Effect of various disease states on theophylline plasma levels and on pulmonary function in patients with chronic airway obstruction treated with a sustained release theophylline preparation. Int J Clin Pharmacol Ther Toxicol. 1987;25:401–5.
38.
go back to reference Martínez-Sellés M, García Robles JA, Muñoz R, et al. Pharmacological treatment in patients with heart failure: patients knowledge and occurrence of polypharmacy, alternative medicine and immunizations. Eur J Heart Fail. 2004;6:219–26.CrossRefPubMed Martínez-Sellés M, García Robles JA, Muñoz R, et al. Pharmacological treatment in patients with heart failure: patients knowledge and occurrence of polypharmacy, alternative medicine and immunizations. Eur J Heart Fail. 2004;6:219–26.CrossRefPubMed
39.
go back to reference Dal Corso E, Bondiani AL, Zanolla L, Vassanelli C. Nurse educational activity on non-prescription therapies in patients with chronic heart failure. Eur J Cardiovasc Nurs. 2007;6:314–20.CrossRef Dal Corso E, Bondiani AL, Zanolla L, Vassanelli C. Nurse educational activity on non-prescription therapies in patients with chronic heart failure. Eur J Cardiovasc Nurs. 2007;6:314–20.CrossRef
40.
go back to reference Entresto (sacubitril and valsartan) [prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation; 2015. Entresto (sacubitril and valsartan) [prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation; 2015.
41.
go back to reference Corlanor (ivabradine) [prescribing information]. Thousand Oaks: Amgen; 2015. Corlanor (ivabradine) [prescribing information]. Thousand Oaks: Amgen; 2015.
42.
go back to reference Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–88.CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–88.CrossRefPubMed
43.
go back to reference Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.CrossRefPubMed
44.
go back to reference Bucci C, Jackevicius C, McFarlane K, Liu P. Pharmacist’s contribution in a heart function clinic: patient perception and medication appropriateness. Can J Cardiol. 2003;19:391–6.PubMed Bucci C, Jackevicius C, McFarlane K, Liu P. Pharmacist’s contribution in a heart function clinic: patient perception and medication appropriateness. Can J Cardiol. 2003;19:391–6.PubMed
45.
go back to reference Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:715–25.CrossRefPubMed Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective β-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:715–25.CrossRefPubMed
46.
go back to reference Doucette D, Goodine C, Symes J, Clarke E. Patients’ recall of interaction with a pharmacist during hospital admission. Can J Hosp Pharm. 2013;66:171–6.PubMedPubMedCentral Doucette D, Goodine C, Symes J, Clarke E. Patients’ recall of interaction with a pharmacist during hospital admission. Can J Hosp Pharm. 2013;66:171–6.PubMedPubMedCentral
47.
go back to reference Slack LR, Ing L. Prevalence and satisfaction of discharged patients who recall interacting with a pharmacist during a hospital stay. Can J Hosp Pharm. 2009;62:204–8.PubMedPubMedCentral Slack LR, Ing L. Prevalence and satisfaction of discharged patients who recall interacting with a pharmacist during a hospital stay. Can J Hosp Pharm. 2009;62:204–8.PubMedPubMedCentral
48.
go back to reference Morecroft CW, Thornton D, Caldwell NA. Inpatients’ expectations and experiences of hospital pharmacy services: qualitative study. Health Expect. 2015;18:1009–17.CrossRefPubMed Morecroft CW, Thornton D, Caldwell NA. Inpatients’ expectations and experiences of hospital pharmacy services: qualitative study. Health Expect. 2015;18:1009–17.CrossRefPubMed
49.
go back to reference Schell W. A review: discharge navigation and its effect on heart failure readmissions. Prof Case Manag. 2014;19:224–34.CrossRefPubMed Schell W. A review: discharge navigation and its effect on heart failure readmissions. Prof Case Manag. 2014;19:224–34.CrossRefPubMed
51.
go back to reference Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168:687–94.CrossRefPubMed Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168:687–94.CrossRefPubMed
52.
go back to reference Lekura J, Tita C, Lanfear DE, Williams CT, Jennings DL. Assessing the potential of e-mail for communicating drug therapy recommendations to physicians in patients with heart failure and ventricular-assist devices. J Pharm Pract. 2014;27:478–80.CrossRefPubMed Lekura J, Tita C, Lanfear DE, Williams CT, Jennings DL. Assessing the potential of e-mail for communicating drug therapy recommendations to physicians in patients with heart failure and ventricular-assist devices. J Pharm Pract. 2014;27:478–80.CrossRefPubMed
53.
go back to reference Kalista T, Lemay V, Cohen L. Postdischarge community pharmacist-provided home services for patients after hospitalization for heart failure. J Am Pharm Assoc. 2003;2015(55):438–42. Kalista T, Lemay V, Cohen L. Postdischarge community pharmacist-provided home services for patients after hospitalization for heart failure. J Am Pharm Assoc. 2003;2015(55):438–42.
54.
go back to reference Lowrie R, Johansson L, Forsyth P, Bryce SL, McKellar S, Fitzgerald N. Experiences of a community pharmacy service to support adherence and self-management in chronic heart failure. Int J Clin Pharm. 2014;36:154–62.CrossRefPubMed Lowrie R, Johansson L, Forsyth P, Bryce SL, McKellar S, Fitzgerald N. Experiences of a community pharmacy service to support adherence and self-management in chronic heart failure. Int J Clin Pharm. 2014;36:154–62.CrossRefPubMed
56.
go back to reference Noureldin M, Plake KS, Morrow DG, Tu W, Wu J, Murray MD. Effect of health literacy on drug adherence in patients with heart failure. Pharmacotherapy. 2012;32:819–26.CrossRefPubMed Noureldin M, Plake KS, Morrow DG, Tu W, Wu J, Murray MD. Effect of health literacy on drug adherence in patients with heart failure. Pharmacotherapy. 2012;32:819–26.CrossRefPubMed
57.
go back to reference Collins SA, Currie LM, Bakken S, Vawdrey DK, Stone PW. Health literacy screening instruments for eHealth applications: a systematic review. J Biomed Inform. 2012;45:598–607.CrossRefPubMedPubMedCentral Collins SA, Currie LM, Bakken S, Vawdrey DK, Stone PW. Health literacy screening instruments for eHealth applications: a systematic review. J Biomed Inform. 2012;45:598–607.CrossRefPubMedPubMedCentral
58.
go back to reference Griffin JM, Partin MR, Noorbaloochi S, et al. Variation in estimates of limited health literacy by assessment instruments and non-response bias. J Gen Intern Med. 2010;25:675–81.CrossRefPubMedPubMedCentral Griffin JM, Partin MR, Noorbaloochi S, et al. Variation in estimates of limited health literacy by assessment instruments and non-response bias. J Gen Intern Med. 2010;25:675–81.CrossRefPubMedPubMedCentral
59.
go back to reference Osborn CY, Weiss BD, Davis TC, et al. Measuring adult literacy in health care: performance of the newest vital sign. Am J Health Behav. 2007;31(Suppl 1):S36–46.CrossRefPubMed Osborn CY, Weiss BD, Davis TC, et al. Measuring adult literacy in health care: performance of the newest vital sign. Am J Health Behav. 2007;31(Suppl 1):S36–46.CrossRefPubMed
60.
go back to reference Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Pharm. 2014;20:741–55. Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Pharm. 2014;20:741–55.
62.
go back to reference Nundy S, Razi RR, Dick JJ, et al. A text messaging intervention to improve heart failure self-management after hospital discharge in a largely African–American population: before-after study. J Med Internet Res. 2013;15:e53.CrossRefPubMedPubMedCentral Nundy S, Razi RR, Dick JJ, et al. A text messaging intervention to improve heart failure self-management after hospital discharge in a largely African–American population: before-after study. J Med Internet Res. 2013;15:e53.CrossRefPubMedPubMedCentral
63.
go back to reference Burke LE, Ma J, Azar KM, et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation. 2015;132:1157–213.CrossRefPubMed Burke LE, Ma J, Azar KM, et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation. 2015;132:1157–213.CrossRefPubMed
65.
go back to reference Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132:873–98.CrossRefPubMed Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132:873–98.CrossRefPubMed
Metadata
Title
A Review of the Role of the Pharmacist in Heart Failure Transition of Care
Authors
Sarah L. Anderson
Joel C. Marrs
Publication date
01-03-2018
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 3/2018
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-018-0671-7

Other articles of this Issue 3/2018

Advances in Therapy 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine